ArticleBMJ open2020

Study protocol: a multicentre, prospective, phase II trial of isotoxic hypofractionated concurrent chemoradiotherapy for non-small cell lung cancer.

Yue-E Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.